We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

414 hedge funds and large institutions have $14B invested in BioMarin Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 159 increasing their positions, 150 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

98.49% more ownership

Funds ownership: 0% → 98.49% (+98%)

6% more repeat investments, than reductions

Existing positions increased: 159 | Existing positions reduced: 150

0% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 57

5% less call options, than puts

Call options by funds: $90.6M | Put options by funds: $95.7M

2% less funds holding

Funds holding: 422 → 414 (-8)

9% less capital invested

Capital invested by funds: $15.4B → $14B (-$1.35B)

15% less funds holding in top 10

Funds holding in top 10: 13 → 11 (-2)

Holders
414
Holders Change
-8
Holders Change %
-1.9%
% of All Funds
10.35%
Holding in Top 10
11
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-15.38%
% of All Funds
0.28%
New
57
Increased
159
Reduced
150
Closed
57
Calls
$90.6M
Puts
$95.7M
Net Calls
-$5.06M
Net Calls Change
-$8.09M

Top Buyers

1
MNA
Manning & Napier Advisors
New York
+$162M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$84M
3
Viking Global Investors
Viking Global Investors
Connecticut
+$78.1M
4
Primecap Management
Primecap Management
California
+$66.9M
5
HM
HealthCor Management
New York
+$66.6M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$120M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$102M
3
Sands Capital Management
Sands Capital Management
Virginia
-$72.3M
4
Capital Research Global Investors
Capital Research Global Investors
California
-$49.3M
5
FAM
Fred Alger Management
New York
-$48.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
FM
326
Family Management
New York
$249K – – –
PAA
327
Peregrine Asset Advisers
Oregon
$249K – – –
SGS
328
Sterling Global Strategies
California
$249K – – –
MIS
329
Morningstar Investment Services
Illinois
$246K +$6.79K +79 +3%
PCM
330
Prelude Capital Management
New York
$240K +$75K +872 +43%
CCIA
331
Campbell & Co Investment Adviser
Maryland
$240K +$250K +2,902 New
Mirae Asset Global Investments
332
Mirae Asset Global Investments
South Korea
$235K -$162K -1,884 -40%
Envestnet Asset Management
333
Envestnet Asset Management
Illinois
$235K +$86 +1 +0%
B
334
BancorpSouth
Mississippi
$223K – – –
LPL Financial
335
LPL Financial
California
$218K +$222K +2,582 New
PCM
336
Palisade Capital Management
New Jersey
$215K -$115K -1,333 -34%
WC
337
Weatherbie Capital
Massachusetts
$215K -$78.1K -908 -26%
LTFS
338
Ladenburg Thalmann Financial Services
Florida
$215K -$1.55K -18 -0.7%
Walleye Trading
339
Walleye Trading
New York
$212K -$52.7K -613 -19%
FAAS
340
First Allied Advisory Services
California
$209K -$33.5K -390 -13%
TAM
341
Tocqueville Asset Management
New York
$207K -$3.64M -42,275 -94%
DCM
342
Dupont Capital Management
Delaware
$189K +$196K +2,280 New
Northwestern Mutual Wealth Management
343
Northwestern Mutual Wealth Management
Wisconsin
$165K +$172K +2,002 New
QI
344
QS Investors
New York
$148K – – –
MOACM
345
Mutual of America Capital Management
New York
$143K -$11.4K -132 -7%
Toronto Dominion Bank
346
Toronto Dominion Bank
Ontario, Canada
$123K +$6.79K +79 +6%
LIA
347
LS Investment Advisors
Michigan
$120K – – –
CAW
348
Cornerstone Advisors (Washington)
Washington
$114K +$18.2K +212 +18%
IPC
349
Independent Portfolio Consultants
Florida
$105K -$3.87K -45 -3%
LWCFA
350
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$91K – – –
12 13
14
15 16

BMRN Hedge Fund Activity: Q4 2016 in Review

414 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2016, worth a combined $14B — down 8.8% from $15.4B a quarter earlier.

Fund positioning in BMRN was balanced in Q4 2016: 57 funds opened new positions, 57 closed out, 159 added to existing stakes and 150 trimmed.

The largest buyer was Manning & Napier Advisors, adding an estimated $162M. The largest seller was T. Rowe Price Associates, cutting an estimated $120M.

  • 414 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2016, down from 422 in Q3 2016.
  • Funds reported $14B of BioMarin Pharmaceuticals stock for Q4 2016, down 8.8% quarter-over-quarter.
  • 57 funds opened new BioMarin Pharmaceuticals positions in Q4 2016 and 57 closed out, a net change of 0 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2016 was Manning & Napier Advisors, an estimated $162M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2016 was T. Rowe Price Associates, an estimated $120M sold.

Based on aggregated 13F filings for Q4 2016.